REPRODUCTIVE HEALTH: R&D FOR THE DEVELOPING WORLD
POLICY CURES

• An independent non-profit research group

• Innovative ideas and rigorous analysis

• Focussed on R&D for neglected diseases of the developing world
REPRODUCTIVE HEALTH: NOW PART OF THE G-FINDER SURVEY

- G-FINDER: Annual survey of global neglected disease R&D funding
- Now including developing country-specific reproductive health R&D for the first time
- Neutral, comparable, comprehensive analysis
- Commissioned by the Bill & Melinda Gates Foundation
WHY INCLUDE REPRODUCTIVE HEALTH?

The developing world still has:

- **225 million women** who need safe and effective contraception
- **39 million** new cases of chlamydia, gonorrhoea & trichomoniasis in African women alone
- **3.3 million** DALYs lost from postpartum haemorrhage
• Only investments aimed specifically at developing country needs
• Covers 6 reproductive health areas
• Data from 31 organisations
• Captured 355 grants
• All R&D stages
• Reported in 2013 US$
Findings
OVERALL FUNDING

$88m invested in DC-specific reproductive health R&D in 2013
Findings

CONTRACEPTIVES

Contraceptives received nearly $\frac{3}{4}$ of this investment.
Findings

FUNDING PER AREA

- Contraceptives: $63m
- Core funding: $9.2m
- MPTs: $6.5m
- Unspecified: $4.0m
- Postpartum haemorrhage: $3.5m
- Platform technologies: $1.8m
- Non-HIV STIs: $0.4m
Findings

FUNDERS

By sector

- Industry: 41%
- Philanthropy: 29%
- Public: 30%

By organisation

- $36m from companies
- $24m from Gates
- $11m from USAID
- Less than $6m from any other funder
Findings
GLOBAL FUNDING DISTRIBUTION

Australia: $0.5 million
Europe: $4.7 million
India: $5.9 million
US: $77 million
Findings
THE MAJOR PRODUCT DEVELOPERS

By sector
- Industry: 45%
- Academic institutes: 21%
- PDPs and intermediaries: 24%
- Public: 9.4%

By organisation
- $40m for companies (mostly self)
- $14m for FHI 360
- $13m for Population Council
- Less than $6m for any other developer
Download the report at http://policycures.org/gfinder.html